The company offers the FDA-cleared Trak Male Fertility Testing System, an at-home test that allows men to learn more about their sperm count level.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.
The funds will support the commercialization of regulated genetic tests to identify molecular drivers of cancer and help individualize treatment strategies.
The acquisition provides Biocrates with complementary skills and technologies, enabling it to serve the metabolomics market as a total solutions provider, it said.
The company, which offers two tests for measuring the soluble ST2 protein in blood, will use the funding to continue global commercialization efforts.
The company recently reached separate deals with Innova Biosciences and Skannex to make it the preferred supplier and partner for lateral flow development and manufacturing with those firms.
The firm's CEO said that the test must undergo additional clinical studies, but it could be available from a CLIA-certified lab in about a year and a half.
The firm is developing a wirelessly enabled biosensor patch that would continuously monitor several blood-glucose biomarkers for diabetes patients.
The new funding comes from life sciences investment firm Perceptive Advisors. Home Care Assistance CEO Lily Sarafan has also joined Counsyl's board.